Merck Reports Improved Overall Survival Results of Keytruda (pembrolizumab) vs Chemotherapy in KEYNOTE-181 Study

 Merck Reports Improved Overall Survival Results of Keytruda (pembrolizumab) vs Chemotherapy in KEYNOTE-181 Study

Merck Reports Improved Overall Survival Results of Keytruda (pembrolizumab) vs Chemotherapy in KEYNOTE-181 Study

 Shots:

  • The P-III KEYNOTE-181 study involves assessing of Keytruda monothx vs CT in 600 patients in ratio (1:1) receiving (Keytruda 200 mg FD q3w) or IV CT (docetaxel /paclitaxel/ irinotecan) in patients with 2L advanced or metastatic esophageal or esophagogastric junction carcinoma
  • The study has shown improved results of OS in patients with CPS ≥10, no new safety signals were observed
  • Keytruda is a mAb serving as an anti-PD-1 therapy for the tumor cells blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2 and is currently studied in 850+ trials globally

Click here to read full press release/ article | Ref: Merck | Image: The Business Journals

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post